AP2005003226A0 - Crystal forms of quinoxaline-2-carboxylic acid[4-carbamoyl-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide. - Google Patents

Crystal forms of quinoxaline-2-carboxylic acid[4-carbamoyl-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide.

Info

Publication number
AP2005003226A0
AP2005003226A0 AP2005003226A AP2005003226A AP2005003226A0 AP 2005003226 A0 AP2005003226 A0 AP 2005003226A0 AP 2005003226 A AP2005003226 A AP 2005003226A AP 2005003226 A AP2005003226 A AP 2005003226A AP 2005003226 A0 AP2005003226 A0 AP 2005003226A0
Authority
AP
ARIPO
Prior art keywords
fluorobenzyl
quinoxaline
carbamoyl
dihydroxy
octyl
Prior art date
Application number
AP2005003226A
Other languages
English (en)
Inventor
Zhengong Bryan Li
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Christopher Stanley Poss
Zheng Jane Li
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2005003226A0 publication Critical patent/AP2005003226A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2005003226A 2002-08-12 2003-07-31 Crystal forms of quinoxaline-2-carboxylic acid[4-carbamoyl-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide. AP2005003226A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12
PCT/IB2003/003464 WO2004014875A1 (en) 2002-08-12 2003-07-31 Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide

Publications (1)

Publication Number Publication Date
AP2005003226A0 true AP2005003226A0 (en) 2005-03-31

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003226A AP2005003226A0 (en) 2002-08-12 2003-07-31 Crystal forms of quinoxaline-2-carboxylic acid[4-carbamoyl-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide.

Country Status (22)

Country Link
US (1) US20040072834A1 (zh)
EP (1) EP1539715A1 (zh)
JP (1) JP2005538130A (zh)
AP (1) AP2005003226A0 (zh)
AR (1) AR040839A1 (zh)
AU (1) AU2003250450A1 (zh)
BR (1) BR0313378A (zh)
CA (1) CA2494776A1 (zh)
EC (1) ECSP055588A (zh)
GT (1) GT200300169A (zh)
IL (1) IL166548A0 (zh)
IS (1) IS7674A (zh)
MX (1) MXPA05001781A (zh)
NO (1) NO20050540L (zh)
OA (1) OA12894A (zh)
PA (1) PA8580401A1 (zh)
PE (1) PE20040866A1 (zh)
TN (1) TNSN05035A1 (zh)
TW (1) TW200407316A (zh)
UY (1) UY27928A1 (zh)
WO (1) WO2004014875A1 (zh)
ZA (1) ZA200500768B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5731538B2 (ja) 2009-12-23 2015-06-10 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｃｒｔｈ２モジュレーター
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (zh) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
KR100447553B1 (ko) * 1997-02-26 2004-09-08 화이자 인코포레이티드 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 ｍｉｐ-1 알파의 ｃｃｒ1 수용체로의 결합에 대한 선택적 저해제로서의 용도
CN1177834C (zh) * 1998-02-05 2004-12-01 辉瑞产品公司 二羟基己酸衍生物

Also Published As

Publication number Publication date
NO20050540L (no) 2005-03-10
UY27928A1 (es) 2004-03-31
US20040072834A1 (en) 2004-04-15
TNSN05035A1 (fr) 2007-05-14
AR040839A1 (es) 2005-04-20
BR0313378A (pt) 2005-07-12
ECSP055588A (es) 2005-04-18
MXPA05001781A (es) 2005-04-25
EP1539715A1 (en) 2005-06-15
OA12894A (en) 2006-10-13
PE20040866A1 (es) 2004-11-26
IL166548A0 (en) 2006-01-15
CA2494776A1 (en) 2004-02-19
ZA200500768B (en) 2006-07-26
WO2004014875A1 (en) 2004-02-19
TW200407316A (en) 2004-05-16
IS7674A (is) 2005-01-27
AU2003250450A1 (en) 2004-02-25
GT200300169A (es) 2004-05-12
PA8580401A1 (es) 2004-02-16
JP2005538130A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
NO20053041D0 (no) Behandling av diabetes.
AU2003283839A1 (en) Heteropolyacid and/or its salt supported catalyst, production process of the catalyst and production process of compound using the catalyst
MXPA03007043A (es) Nueva sal de succinato de o-desmetil-venlafaxina.
ZA200300208B (en) Manufacture of high octane alkylate.
AU2003279744A1 (en) Partially expanded, free flowing, acid treated graphite flake
HRP20050328A2 (en) Process for the preparation of (s,s)-cis-2-benzhyd
AU2003225095A1 (en) Parallel sizing, dosing and transfer assembly and method of use
MXPA03008548A (es) Mejoras en componentes que contienen aroma.
ZA200501624B (en) Flat lamp, production method thereof and application of same.
MXPA03008630A (es) Derivados de arilisoxazolinas, procedimientos para su preparacion y su utilizacion como agentes plaguicidas.
DE60216641D1 (de) Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
IL166548A0 (en) Crystal forms of quinoxaline-2-carboxylic acidÄ4-carbampyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octylÜ-amide
ZA200407361B (en) Acyl-3-carboxyphenylurea derivatives, method for production and use thereof.
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
EG23393A (en) Production of olefins.
AU2003287844A1 (en) Novel crystalline forms of entacapone, and production thereof
AU2003225426A1 (en) Process for the preparation of urea
IL173447A0 (en) Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same
EP1517879A4 (en) AMINOALKYLPHENOLS AND METHODS OF USE AND MANUFACTURE
AU2003272083A1 (en) Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide
AU2003236276A1 (en) Snap electrode, its bonding method and using method
AU2003249935A1 (en) Method for the production of electrically-conducting connections on chipcards
AU2003284815A1 (en) Method for conversion of waveguide modes, mode-converting arrangement and antenna arrangement.
AU2003301681A1 (en) A process for the production of n-(4-cyano-3-trifluoromethylphenyl)-2,3-epoxy-2-methylpropanamide
IL160047A0 (en) Method for the production of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-ylacetic acid